21 June 2013
Cambridge Biomedical Campus has been selected as the site of AstraZeneca/MedImmune’s new global research and development centre and corporate headquarters, in a deal tipped by Property Week.
You must be logged in to continue
Register for free to finish this article.
Sign up now for the following benefits:
To access this article REGISTER NOW